' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit.
Rohracher, A; Hofler, J; Kalss, G; Leitinger, M; Kuchukhidze, G; Deak, I; Dobesberger, J; Novak, H; Pilz, G; Zerbs, A; Trinka, E
EPILEPSY BEHAV. 2015; 49: 354-358.
Originalarbeiten (Zeitschrift)


Astner-Rohracher Alexandra
Deak Ildiko
Dobesberger Judith
Höfler Julia
Kalss Gudrun
Kuchukhidze Giorgi
Leitinger Markus
Novak Helmut
Pilz Georg
Trinka Eugen
Zerbs Alexander


In refractory status epilepticus (SE), because of subcellular maladaptive changes, GABAergic drugs are no longer effective, and the excitatory neurotransmitter glutamate (Glu) plays a major role in seizure perpetuation. Perampanel (PER, licensed since 09/2012) is the first orally active noncompetitive AMPA receptor antagonist for adjunctive treatment of refractory focal epilepsy.
We analyzed treatment response, seizure outcome, and adverse effects of add-on treatment with perampanel in patients with refractory status epilepticus in the Neurological Intensive Care Unit (NICU), Salzburg, Austria between 09/2012 and 11/2014 by retrospective chart review.
Twelve patients (75% women) with refractory status epilepticus were treated with PER administered per nasogastric tube between 09/2012 and 11/2014. Median age was 75years [range: 60-91]. The most frequent SE type was nonconvulsive SE (NCSE) with (5/12, 42%) and without coma (6/12, 50%). In seven patients (58%), SE arose de novo, with an acute symptomatic cause in five patients (42%). Cerebrovascular diseases (4/12, 33%) and cerebral tumors (4/12, 33%) were the most common etiologies. Perampanel was given after a median number of four antiepileptic drugs [range: 2-7] and a median time of 1.5days [range: 0.8-18.3]. In one patient (8%), clinical improvement was observed within 24h and EEG improvement within 60h after administration of PER, while in another patient (8%), clinical and EEG improvement was observed more than 48h after administration. Median initial dose was 4mg [range: 2-12; SD: 4.11], titrated up to a median of 12mg [range: 4-12] in steps of 2 to 4mgperday. No adverse effects were reported regarding cardiorespiratory changes or laboratory parameters. Outcomes after SE were moderate disability in five patients (42%), death in three patients (25%), and persistent vegetative state in two patients (17%).
Though glutamate plays a major role in seizure perpetuation, the noncompetitive AMPA receptor antagonist PER could only ameliorate seizure activity in a few patients with refractory SE. The long duration of SE before the administration of PER via nasogastric tube, as well as relatively low doses of PER, might be responsible for the modest result. Perampanel was well tolerated, and no adverse events were reported. This article is part of a Special Issue entitled Status Epilepticus.

Find related publications in this database (Keywords)

Refractory status epilepticus
Noncompetitive AMPA receptor antagonist